ScreenerHero

GDTCCytoMed Therapeutics Limited Ordinary Shares

NAS · US · Healthcare · Biotechnology · w2.cytomed.sg
1.030USDMkt Cap: 12.19M $P/E: —

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap12.19M $
Enterprise Value9.34M $
Revenue (TTM)860.85K $
Gross Profit256.39K $
Net Income (TTM)-3.98M $
Revenue/Share0.0740 USD
Last Price1.030 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees42
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.99
PEG—
EV/EBITDA-2.43
EV/Revenue10.85
P/S12.36
P/B2.08
EPS (TTM)-0.27
EPS (Forward)-0.15
52W Range
0.8559100% of range1.030
52W High1.030 USD
52W Low0.8559 USD
Profitability
Gross Margin79.04%
Oper. Margin-535.25%
EBITDA Margin0.00%
Profit Margin-1227.07%
ROE-60.82%
ROA-49.85%
Growth
Revenue Growth46.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.70M $
CapEx (TTM)703.13K $
FCF Margin-315.43%
FCF Yield-22.28%
Net Debt-1.61M $
Net Debt/EBITDA0.42
Balance Sheet
Debt/Equity0.07
Current Ratio5.17
Quick Ratio3.14
Book Value/Sh0.4327 USD
Cash/Share0.1770 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.11.83M
Float3.49M
Insiders70.47%
Institutions0.14%
Short Interest
Short Ratio0.0d
Short % Float0.16%
Short % Out.0.05%
Shares Short5.66K
Short (prev mo.)37.91K
Technical
SMA 500.9699 (+6.2%)
SMA 2001.178 (-12.5%)
Beta0.05
S&P 52W Chg21.00%
Avg Vol (30d)54.48K
Avg Vol (10d)30.11K
Technical Indicators
RSI (14)59.6
MACD-0.0068
MACD Signal-0.0265
MACD Hist.+0.0197
BB Upper1.014 USD
BB Middle0.8895 USD
BB Lower0.7646 USD
BB Width28.09%
ATR (14)0.0970 USD
Vol Ratio (20d)0.25x